Language: Spanish
References: 18
Page: 274-279
PDF size: 67.48 Kb.

ABSTRACT

Mivacurium chloride, a short-acting nondepolarizing neurumuscular agent is recently in use. It’s a bis-benzilisoquinolinium diester compund, with a recomended dose of 0.15-0.2 mg/kg^-1 provides good intubating conditions in 2.5 minutes after injection and has a duration of 15-30 minutes, for this reason, its has been recomended using with infusion rate in intermediate’s surgery with no haemodinamic repercussion in myastenic, anephric, geriatric or hepatic failure patients. In these cases the duration of this substance must be prolonged. It is shown a case in a geritric emergency appendicetomy with plasmatic cholinesterase deficience.

REFERENCES

1. Muravchick S. Anaesthesia for the aging patient. Can J Anaesth 1993; 40 (5): R63-68.

2. Maddineni VR, Mirakhur RK, Mc Coy EP, Sharpe TD. Neuromuscular and haemodynamic effects of mivacurium in elderly and young patients. Br J Anaesthesia 1994; 73: 608-612.

3. Katoh T, Suguro Y, Ikeda T, Kazama T, Ikeda K. Influence of age on awakening concentrations of sevoflurane and isoflurane. Anesth Analg 1993; 76: 348-352.

4. Phillips BJ, Hunter JM. Use of mivacurium chloride by constant infusion in the anephric patient. Br J Anaesthesia 1992; 68: 492-498.

5. Patterson IG, Hood JR, Russell SH, Weston MD, Hirsch NP. Mivacurium in the myastenic patient. Br J Anaesthesia 1994; 73: 494-498.

6. Baurain MJ, Dernovoi BS, Hollander AA, Hennart DA. Comparison of neostigmine-induced recovery with spontaneous recovery from mivacurium-induced neuromuscular block. Br J Anaesthesia 1994; 73: 791-794.

7. Fox MH, Hunt PC. Prolonged neuromuscular block associated with mivacurium. Br J Anaesthesia 1995; 74 (2): 237.

8. Stone JG, Matteo RS, Ornstein E, Schwartz A, Ostapkovich N, Jamdar SC. Aging alters the pharmacokinetics of pyridostigmine. Anesth Analg 1995; 81: 773-776.

9. Naguib M, El-Gammal M, Daoud W, Ammar A, Moukhtar H, Turkistani A et al. Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade. Anesthesiology 1995; 82: 1288-1292.

10. Ostergaard D, Jensen F, Viby-Mogensen J. Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase. Anesthesiology 1995; 82: 1295-1298.

11. Naguib M, Daoud W, El-Gammal M, Ammar A, Turkistani A, Selim W et al. Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase. Anesthesiology 1995; 83: 694-701.

12. Naguib M, Samarkandi H, Bakhamees HS, Turkistani A, Alpharby W. Edrophonium and human plasma cholinesterase combination for antagonism of mivacurium-induced neuromuscular block. Br J Anaesthesia 1996; 77: 424-426.

13. Cordero EI. Avances en el campo de los relajantes musculares. Fármacos de reciente empleo. Analgesia en México 1997; 9 (5): 164-168.

14. Difenbach Ch, Mellinghoff H, Lynch J, Buzello W. Mivacurium: Dose-response relationship and administration by repeated injection or infusion. Anesth Analg 1992; 74: 420-423.

15. Hart P, McCarthy G, Brown R, Lau M, Fisher D. The effect of plasma cholinesterase activity on mivacurium infusion rates. Anesth Analg 1995; 80: 760-763.

16. Cook DR, Freeman AA, Lai AA, Kay Y, Stiller RL, Welch RM. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth 1992; 69: 580-585.

17. Aziz L, Ono K, Ohta Y, Morita K, Hirakawa M. The effect of CO2-induced acid-base changes on the potencies of muscle relaxants and antagonism of neuromuscular block by neostigmine in rat in vitro. Anesth Analg 1994; 78: 322-327.

18. Aziz L, Ono K, Ohta Y, Morita K, Hirakawa M. Effect of hypothermia on the in vitro potencies of neuromuscular blocking agents and their antagonism by neostigmine. Br J Anaesth 1994; 73: 662-666.